Sydney, Australia, 5 September 2018:
Minomic International Ltd (Minomic), an immuno-oncology company specializing in the commercialization and development of diagnostics and therapeutics for solid tumors, including prostate, bladder and pancreas has announced the grant of its patent ‘Cell surface prostate cancer antigen for diagnosis’ in the key global markets of the United States of America and China.
Improved accuracy and sensitivity in prostate cancer diagnosis remains a significant unmet medical need. Prostate cancer is one of the most common cancers in the USA with a significant increase in incidence and mortality also being observed in China. Substantial numbers of men would benefit from the improvements in prostate cancer diagnosis that Minomic’s new technology could provide.
The Company has discovered that glypican-1 is a new marker for prostate cancer with elevated levels detected in the body fluids or tissues of prostate cancer patients. The invention provides compositions and methods of detecting prostate cancer in the body fluids or tissues of patients, where prostate cancer is detected by measuring, with other markers, the level of glypican-1. The identified markers may also be used in determining prognosis and monitoring response to treatment for prostate cancer patients.
The Company said China and the US are the latest in the list of countries where the patent has now been granted.
Minomic’s CEO, Dr Brad Walsh, noted “Improving prostate cancer diagnostics and ensuring appropriate treatments are used in a timely fashion have the capacity to greatly decrease mortality and morbidity associated with this disease. The granting of this patent in these key markets also strengthens Minomic’s IP portfolio enhancing the company’s business development efforts.”
The scientific data behind Minomic’s patent technology was recently presented at the 3rd Global Summit on Precision Diagnosis and Treatment of Prostate Cancer in Boston in August 2018, with further clinical data recently submitted for publication.